Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, announced today that it will report second quarter 2022 earnings...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a...
Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, today announced that its Specialty Generics business has been...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will report second quarter 2020 earnings results for the...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U....
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced publication of findings from a medical chart study to assess the...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that its observational registry comparing the safety and...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it is supporting an investigator-initiated clinical study at...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced the publication of findings from its randomized,...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Novoteris, LLC, a clinical stage medical device and pharmaceutical developer...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced the completion of its rolling submission of a New Drug Application...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today commented that it is currently evaluating the limited published evidence...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced publication of findings from a prospective, open-label pilot study...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced findings from a retrospective medical record analysis to assess...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it initiated the rolling submission of a New Drug Application (NDA) ...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will present new data from two studies of Acthar® Gel...
La multinationale biopharmaceutique Mallinckrodt plc (NYSE: MNK) a annoncé aujourd'hui l'autorisation réglementaire d'UVADEX™ (méthoxsalène) en...
Mallinckrodt plc (NYSE: MNK), ein globales Biopharma-Unternehmen, hat heute bekannt gegeben, dass UVADEX® (Methoxsalen) in Australien durch die...
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that UVADEX® (methoxsalen) has received regulatory approval in...
Mallinckrodt plc (NYSE : MNK), une société biopharmaceutique mondiale, a annoncé l'ouverture du 2020 Advancing Extracorporeal Photopheresis (ECP)...
Mallinckrodt plc (NYSE: MNK), una compañía biofarmacéutica global, ha anunciado que está abierto el periodo de inscripción para su Premio al...
Mallinckrodt plc (NYSE: MNK), azienda biofarmaceutica attiva su scala globale, ha aperto le candidature all'Investigator Award 2020 per i progressi...
Mallinckrodt plc (NYSE: MNK), ein globales biopharmazeutisches Unternehmen, kündigte an, dass ab sofort Bewerbungen für den Forschungspreis „2020...
Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present at the Cantor Global Healthcare Conference at the...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.